Name: Juvmo (tavapadon) in Parkinson's disease: Pharmacodynamics
Published: 2026-09-27T21:44:59-04:00

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

7 evidence topics · 6 sources

Cardiac electrophysiology

“At the maximum recommended JUVMO dosage of 15 mg once daily, a mean increase in the QTc interval >20 ms is unlikely.” (opens the prescribing information at this quote)

QTc interval in the Phase 1 studies in Parkinson's disease

“There appeared to be a small dose-related increase in QT interval corrected for heart rate using Fridericia’s formula (QTcF) at the 2, 4, and 8 h post dose time points.” (opens the source at this quote in a new tab)
“The greatest increase from baseline in mean QTcF at any time point for any dose group was 11.7 ms.” (opens the source at this quote in a new tab)
“Despite these observations in the SAD study, no QTcF prolongation was observed in the MAD study, where higher PF-06649751 exposures were achieved, and no subject had a QTcF ≥ 500 ms or an increase of QTcF ≥ 60 ms.” (opens the source at this quote in a new tab)

Blood pressure effects in the Phase 3 trials

“In the TEMPO-1, tavapadon resulted in BP reductions during the initial titration, with a mean (standard deviation [SD]) reduction of −6.7 (7.31) mmHg in supine diastolic BP with tavapadon versus a mean increase of 0.1 (7.45) mmHg with placebo at week 27.” (opens the source at this quote in a new tab)
“The mean (SD) reduction in supine systolic BP at week 27 was −12.0 (13.17) mmHg with tavapadon and −1.7 (12.25) mmHg with placebo.” (opens the source at this quote in a new tab)
“These changes decreased gradually during treatment with tavapadon.” (opens the source at this quote in a new tab)

Cardiovascular effects in early-phase trials

“tavapadon produced only modest dose-related changes in cardiovascular measures that were not clinically meaningful” (opens the source at this quote in a new tab)
“Tavapadon produced consistent but mild decreases in systolic and diastolic blood pressure, increases in heart rate, and modest changes in other cardiovascular parameters.” (opens the source at this quote in a new tab)

Onset and duration of motor effect after single doses

“On the first day of treatment with 9.0 mg of tavapadon, patients showed a significant reduction in motor symptoms compared with placebo starting one hour after drug administration, as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS-III)” (opens the source at this quote in a new tab)
“Importantly, these improvements were sustained for at least 12 hours after treatment, providing further support for a once-daily dosing regimen” (opens the source at this quote in a new tab)

Nonhuman primate model: motor effect, dyskinesia, and receptor occupancy

“Here, we demonstrate, in a clinically translatable nonhuman primate model of parkinsonian motor symptoms, that treatment with the partial D1 receptor agonist CVL-751, formerly known as PF-06649751, is just as effective as L-DOPA in enabling movement and reducing disability.” (opens the source at this quote in a new tab)
“Importantly, CVL-751 efficacy is observed with less of the concomitant dyskinesia side effect associated with L-DOPA treatment.” (opens the source at this quote in a new tab)

“The peak receptor occupancy at D1 receptors was estimated to be 48% following the administration of 0.1 mg/kg of tavapadon, a dose that led to motor improvements comparable to those seen following levodopa administration” (opens the source at this quote in a new tab)
“Motor improvements following tavapadon administration were sustained for more than twice as long as those seen following treatment with levodopa, supporting potential sustained motor benefit with tavapadon” (opens the source at this quote in a new tab)

Striatal and cortical electrophysiology in mice

“In contrast to its effect in the mPFC, 1 μM tavapadon significantly potentiated the IPSC in the SNr (123.1% of baseline, p < 0.05).” (opens the source at this quote in a new tab)
“However, perfusing 1 μM tavapadon did not enhance the cortical EPSC amplitude (Figures 5B and 5C).” (opens the source at this quote in a new tab)